The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: A cross sectional comparative study

Samer Hammoudeh, Suhaila Ghuloum, Ziyad Mahfoud, Arij Yehya, Abdulmoneim Abdulhakam, Azza Al-Mujalli, Mahmoud Al-Zirie, Mohamed Osman Abdel Rahman, Angela Godwin, Noura Younes, Yahya Hani, Dennis Mook-Kanamori, Marjonneke Mook-Kanamori, Reem El Sherbiny, Hassen Al Amin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Metabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on antipsychotics relative to controls in Qatar, and to assess the factors contributing to the development of MetS. Methods: A cross sectional design was used to collect data and fasting blood samples from subjects maintained on antipsychotics for at least six months (n = 112) and from a control group (n = 114). The groups were compared in regard to prevalence of MetS, and multiple regression analysis was used to determine the risk factors in each group. Results: The two groups (antipsychotics vs. control) were similar in regard to age (35.73 ± 10.28 vs. 35.73 ± 8.16 years) and gender ratio. The MetS was higher among the subjects on antipsychotics, but this difference did not reach statistical significance. Blood pressure (BP) was significantly higher in the antipsychotics group and BMI was the major risk factor to develop MetS in this group. Conclusions: The prevalence of MetS in both groups is high and mostly attributed to obesity and high BP. Public health interventions are needed to address this major health problem overall. Larger studies are needed to further assess the impact of antipsychotics and mental illness on the development of MetS.

Original languageEnglish
Article number81
JournalBMC Psychiatry
Volume18
Issue number1
DOIs
Publication statusPublished - 27 Mar 2018

Fingerprint

Qatar
Antipsychotic Agents
Cross-Sectional Studies
Fasting
Cardiovascular Diseases
Public Health
Obesity
Regression Analysis
Blood Pressure
Hypertension
Control Groups
Mortality
Health

Keywords

  • Antipsychotics
  • Arabs
  • Mental illness
  • Metabolic syndrome

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar : A cross sectional comparative study. / Hammoudeh, Samer; Ghuloum, Suhaila; Mahfoud, Ziyad; Yehya, Arij; Abdulhakam, Abdulmoneim; Al-Mujalli, Azza; Al-Zirie, Mahmoud; Abdel Rahman, Mohamed Osman; Godwin, Angela; Younes, Noura; Hani, Yahya; Mook-Kanamori, Dennis; Mook-Kanamori, Marjonneke; El Sherbiny, Reem; Al Amin, Hassen.

In: BMC Psychiatry, Vol. 18, No. 1, 81, 27.03.2018.

Research output: Contribution to journalArticle

Hammoudeh, S, Ghuloum, S, Mahfoud, Z, Yehya, A, Abdulhakam, A, Al-Mujalli, A, Al-Zirie, M, Abdel Rahman, MO, Godwin, A, Younes, N, Hani, Y, Mook-Kanamori, D, Mook-Kanamori, M, El Sherbiny, R & Al Amin, H 2018, 'The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: A cross sectional comparative study', BMC Psychiatry, vol. 18, no. 1, 81. https://doi.org/10.1186/s12888-018-1662-6
Hammoudeh, Samer ; Ghuloum, Suhaila ; Mahfoud, Ziyad ; Yehya, Arij ; Abdulhakam, Abdulmoneim ; Al-Mujalli, Azza ; Al-Zirie, Mahmoud ; Abdel Rahman, Mohamed Osman ; Godwin, Angela ; Younes, Noura ; Hani, Yahya ; Mook-Kanamori, Dennis ; Mook-Kanamori, Marjonneke ; El Sherbiny, Reem ; Al Amin, Hassen. / The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar : A cross sectional comparative study. In: BMC Psychiatry. 2018 ; Vol. 18, No. 1.
@article{4a5c94eb033c43dbbe88baf71d51f25f,
title = "The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: A cross sectional comparative study",
abstract = "Background: Metabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on antipsychotics relative to controls in Qatar, and to assess the factors contributing to the development of MetS. Methods: A cross sectional design was used to collect data and fasting blood samples from subjects maintained on antipsychotics for at least six months (n = 112) and from a control group (n = 114). The groups were compared in regard to prevalence of MetS, and multiple regression analysis was used to determine the risk factors in each group. Results: The two groups (antipsychotics vs. control) were similar in regard to age (35.73 ± 10.28 vs. 35.73 ± 8.16 years) and gender ratio. The MetS was higher among the subjects on antipsychotics, but this difference did not reach statistical significance. Blood pressure (BP) was significantly higher in the antipsychotics group and BMI was the major risk factor to develop MetS in this group. Conclusions: The prevalence of MetS in both groups is high and mostly attributed to obesity and high BP. Public health interventions are needed to address this major health problem overall. Larger studies are needed to further assess the impact of antipsychotics and mental illness on the development of MetS.",
keywords = "Antipsychotics, Arabs, Mental illness, Metabolic syndrome",
author = "Samer Hammoudeh and Suhaila Ghuloum and Ziyad Mahfoud and Arij Yehya and Abdulmoneim Abdulhakam and Azza Al-Mujalli and Mahmoud Al-Zirie and {Abdel Rahman}, {Mohamed Osman} and Angela Godwin and Noura Younes and Yahya Hani and Dennis Mook-Kanamori and Marjonneke Mook-Kanamori and {El Sherbiny}, Reem and {Al Amin}, Hassen",
year = "2018",
month = "3",
day = "27",
doi = "10.1186/s12888-018-1662-6",
language = "English",
volume = "18",
journal = "BMC Psychiatry",
issn = "1471-244X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar

T2 - A cross sectional comparative study

AU - Hammoudeh, Samer

AU - Ghuloum, Suhaila

AU - Mahfoud, Ziyad

AU - Yehya, Arij

AU - Abdulhakam, Abdulmoneim

AU - Al-Mujalli, Azza

AU - Al-Zirie, Mahmoud

AU - Abdel Rahman, Mohamed Osman

AU - Godwin, Angela

AU - Younes, Noura

AU - Hani, Yahya

AU - Mook-Kanamori, Dennis

AU - Mook-Kanamori, Marjonneke

AU - El Sherbiny, Reem

AU - Al Amin, Hassen

PY - 2018/3/27

Y1 - 2018/3/27

N2 - Background: Metabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on antipsychotics relative to controls in Qatar, and to assess the factors contributing to the development of MetS. Methods: A cross sectional design was used to collect data and fasting blood samples from subjects maintained on antipsychotics for at least six months (n = 112) and from a control group (n = 114). The groups were compared in regard to prevalence of MetS, and multiple regression analysis was used to determine the risk factors in each group. Results: The two groups (antipsychotics vs. control) were similar in regard to age (35.73 ± 10.28 vs. 35.73 ± 8.16 years) and gender ratio. The MetS was higher among the subjects on antipsychotics, but this difference did not reach statistical significance. Blood pressure (BP) was significantly higher in the antipsychotics group and BMI was the major risk factor to develop MetS in this group. Conclusions: The prevalence of MetS in both groups is high and mostly attributed to obesity and high BP. Public health interventions are needed to address this major health problem overall. Larger studies are needed to further assess the impact of antipsychotics and mental illness on the development of MetS.

AB - Background: Metabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on antipsychotics relative to controls in Qatar, and to assess the factors contributing to the development of MetS. Methods: A cross sectional design was used to collect data and fasting blood samples from subjects maintained on antipsychotics for at least six months (n = 112) and from a control group (n = 114). The groups were compared in regard to prevalence of MetS, and multiple regression analysis was used to determine the risk factors in each group. Results: The two groups (antipsychotics vs. control) were similar in regard to age (35.73 ± 10.28 vs. 35.73 ± 8.16 years) and gender ratio. The MetS was higher among the subjects on antipsychotics, but this difference did not reach statistical significance. Blood pressure (BP) was significantly higher in the antipsychotics group and BMI was the major risk factor to develop MetS in this group. Conclusions: The prevalence of MetS in both groups is high and mostly attributed to obesity and high BP. Public health interventions are needed to address this major health problem overall. Larger studies are needed to further assess the impact of antipsychotics and mental illness on the development of MetS.

KW - Antipsychotics

KW - Arabs

KW - Mental illness

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=85044502448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044502448&partnerID=8YFLogxK

U2 - 10.1186/s12888-018-1662-6

DO - 10.1186/s12888-018-1662-6

M3 - Article

C2 - 29587717

AN - SCOPUS:85044502448

VL - 18

JO - BMC Psychiatry

JF - BMC Psychiatry

SN - 1471-244X

IS - 1

M1 - 81

ER -